NCT05193279View on ClinicalTrials.gov

Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 5, 2022

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Candidate vaccine, SCB-2019

a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19

Trial Locations (2)

080020

Clínica de la Costa Ltda, Barranquilla

Unknown

Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S., Santiago de Cali

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY